Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Evidence of Lung Function for Stratification of Cardiovascular Disease Risk

  • Lee, Hwa-Mu (Heart Disease Prevention Program, Divisions of Cardiology, Department of Medicine, University of California) ;
  • Truong, Steven T. (Heart Disease Prevention Program, Divisions of Cardiology, Department of Medicine, University of California) ;
  • Wong, Nathan D. (Heart Disease Prevention Program, Divisions of Cardiology, Department of Medicine, University of California)
  • Published : 2011.04.30
⟨ Previous Next ⟩

Abstract

Among adults in the United States, the prevalence of reduced lung function including obstructive and restrictive lung disease is about 20%, representing an over 40 million adults. Persons with reduced lung function often demonstrate chronic systemic inflammation, such as from elevated levels of C-reactive protein. Substantial data suggests that inflammation may have a significant role in the association between reduced lung function and cardiovascular disease (CVD); however, how reduced lung function predicts CVD as risk modification remains largely unknown. Poor lung function has been shown to be a better predictor of all-cause and cardiac-specific mortality than established risk factors such as serum cholesterol, and CVD is the leading cause of mortality among those with impaired lung function. The exact mechanism of atherosclerosis is not clear, but persistent low grade inflammation is considered as one of the culprits in clot formation. The initial presentation of coronary heart disease is either myocardial infarction or sudden death in approximately half of the individuals. Unfortunately, conventional risk factor assessment predicts only 65-80% of future cardiovascular events, leaving many middle-aged and older individuals to manifest a major cardiovascular event despite being classified low risk by the Framingham risk estimates.

Keywords

References

  1. Gluckman TJ, Baranowski B, Ashen MD, et al. A practical and evid-ence-based approach to cardiovascular disease risk reduction. Arch Intern Med 2004;164:1490-500. https://doi.org/10.1001/archinte.164.14.1490
  2. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascu-lar risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53. https://doi.org/10.1161/CIRCULATIONAHA.107.699579
  3. Thompson JB, Rivera JJ, Blumenthal RS, Danyi P. Primary prevention for patients with intermediate Framingham risk scores. Curr Cardiol Rep 2006;8:261-6. https://doi.org/10.1007/s11886-006-0056-4
  4. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-72. https://doi.org/10.1016/0002-9149(90)90079-G
  5. Ridker PM. Clinical application of C-reactive protein for cardiovascu-lar disease detection and prevention. Circulation 2003;107:363-9. https://doi.org/10.1161/01.CIR.0000053730.47739.3C
  6. Wilson PW, Smith SC Jr, Blumenthal RS, Burke GL, Wong ND. 34th Bethesda conference task force #4: how do we select patients for atherosclerosis imaging? J Am Coll Cardiol 2003;41:1898-906. https://doi.org/10.1016/S0735-1097(03)00361-9
  7. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA writing committee to update the 2000 expert consensus document on electron beam computed tomography) developed in collaboration with the society of atherosclerosis imaging and prevention and the society of cardiovascular computed tomography. J Am Coll Cardiol 2007;49:378-402. https://doi.org/10.1016/j.jacc.2006.10.001
  8. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Don-nell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-7. https://doi.org/10.1161/CIRCOUTCOMES.108.831198
  9. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol 2010;56:e50-103, doi: 10.1016/j.jacc.2010.09.001.
  10. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. https://doi.org/10.1038/nature01323
  11. Nilsson J. CRP: marker or marker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005;25:1527-8. https://doi.org/10.1161/01.ATV.0000174796.81443.3f
  12. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113:2128-34; discussion 2151. https://doi.org/10.1161/CIRCULATIONAHA.105.611350
  13. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham Study. Am Heart J 1983;105: 311-5. https://doi.org/10.1016/0002-8703(83)90532-X
  14. Marcus EB, Curb JD, MacLean CJ, Reed DM, Yano K. Pulmonary fu-nction as a predictor of coronary heart disease. Am J Epidemiol 1989; 129:97-104. https://doi.org/10.1093/oxfordjournals.aje.a115128
  15. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106:2555-60. https://doi.org/10.1161/01.CIR.0000037220.00065.0D
  16. Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003;158:1171-81. https://doi.org/10.1093/aje/kwg276
  17. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-9. https://doi.org/10.1378/chest.127.6.1952
  18. Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch Environ Health 1970;21:418-24. https://doi.org/10.1080/00039896.1970.10667260
  19. Beaty TH, Newill CA, Cohen BH, Tockman MS, Bryant SH, Spurgeon HA. Effects of pulmonary function on mortality. J Chronic Dis 1985;38:703-10. https://doi.org/10.1016/0021-9681(85)90024-4
  20. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington county, Maryland. Am Rev Respir Dis 1989;140:S56-63. https://doi.org/10.1164/ajrccm/140.3_Pt_2.S56
  21. Hole DJ, Watt GC, Darvey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risks in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-5. https://doi.org/10.1136/bmj.313.7059.711
  22. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-64. https://doi.org/10.1378/chest.118.3.656
  23. Curb JD, Marcus EB, Reed DM, MacLean C, Yano K. Smoking, pulmonary function and mortality. Ann Epidemiol 1990;1:25-32. https://doi.org/10.1016/1047-2797(90)90016-L
  24. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Spirometric findings and mortality in never smokers. J Clin Epidemiol 1990;43:867-73. https://doi.org/10.1016/0895-4356(90)90070-6
  25. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9. https://doi.org/10.1161/01.CIR.0000056767.69054.B3
  26. Lee HM, Le H, Lee BT, Lopez VA, Wong ND. Forced vital capacity paired with Framingham risk score for prediction of all-cause mortality. Eur Respir J 2010;36:1002-6. https://doi.org/10.1183/09031936.00042410
  27. Jiang R, Burke GL, Enright PL, et al. Inflammatory markers and lo-ngitudinal lung function decline in the elderly. Am J Epidemiol 2008; 168:602-10. https://doi.org/10.1093/aje/kwn174
  28. Thyagarajan B, Jacobs DR, Apostol GG, Smith LJ, Lewis CE, Williams OD. Plasma fibrinogen and lung function: the CARDIA Study. Int J Epidemiol 2006;35:1001-8. https://doi.org/10.1093/ije/dyl049
  29. Hancox RJ, Poulton R, Greene JM, et al. Systemic inflammation and lung function in young adults. Thorax 2007;62;1064-8. https://doi.org/10.1136/thx.2006.076877
  30. Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir Med 2006;100:2112-20. https://doi.org/10.1016/j.rmed.2006.03.027
  31. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007;62:515-20. https://doi.org/10.1136/thx.2006.066969
  32. Lee HM, Le TV, Lopez VA, Wong ND. Association of C-reactive pro-tein with reduced forced vital capacity in a nonsmoking U. S. popula-tion with metabolic syndrome and diabetes. Diabetes Care 2008;31: 2000-2. https://doi.org/10.2337/dc08-0801
  33. Gan WQ, Man SF, Senthilsevan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80. https://doi.org/10.1136/thx.2003.019588
  34. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the third national he-alth and nutrition examination. Am J Med 2003;114:758-62. https://doi.org/10.1016/S0002-9343(03)00185-2
  35. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60. https://doi.org/10.1016/j.jacc.2006.04.039
  36. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83.
  37. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12. https://doi.org/10.1378/chest.06-1997
  38. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kina-sewitz GT. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-71. https://doi.org/10.1378/chest.07-0298
  39. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006;61:472-7. https://doi.org/10.1136/thx.2005.052449
  40. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 2006; 173:985-90. https://doi.org/10.1164/rccm.200508-1344OC
  41. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systemic review. Chest 2009;136:734-43. https://doi.org/10.1378/chest.09-0194

Cited by

  1. Relationships of Decreased Lung Function with Metabolic Syndrome and Obstructive Sleep Apnea in Japanese Males vol.51, pp.17, 2011, https://doi.org/10.2169/internalmedicine.51.7427
  2. Mesothelioma and lung cancer mortality: A historical cohort study among asbestosis workers in Hong Kong vol.76, pp.2, 2011, https://doi.org/10.1016/j.lungcan.2011.11.003
  3. Role of COPD in Evaluation of Cardiovascular Risk vol.7, pp.2, 2011, https://doi.org/10.1007/s12170-013-0292-2
  4. Increased Cardiometabolic Risk and Worsening Hypoxemia at High Altitude vol.17, pp.2, 2016, https://doi.org/10.1089/ham.2015.0084
  5. The association of reduced lung function with blood pressure variability in African Americans: data from the Jackson Heart Study vol.16, pp.None, 2016, https://doi.org/10.1186/s12872-015-0182-2
  6. Subclinical pulmonary dysfunction contributes to high altitude pulmonary edema susceptibility in healthy non-mountaineers vol.7, pp.None, 2011, https://doi.org/10.1038/s41598-017-14947-z
  7. Long-term Air Pollution Exposure, Genome-wide DNA Methylation and Lung Function in the LifeLines Cohort Study vol.126, pp.2, 2011, https://doi.org/10.1289/ehp2045